Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?

Authors: David Groheux MD, PhD1, Elif Hindié MD, PhD2, Marc Espié MD3, and Gary A. Ulaner MD, PhD4
View More View Less
  • 1 Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France;
  • | 2 Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France;
  • | 3 Breast Diseases Unit, Saint-Louis Hospital, Paris, France; and
  • | 4 Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California
Restricted access
  • 1.

    Hyland CJ, Varghese F, Yau C, et al. Use of 18F-FDG PET/CT as an initial staging procedure for stage II-III breast cancer: a multicenter value analysis. J Natl Compr Canc Netw 2020;18:15101517.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Gradishar WJ, Moran MS, Abraham J, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2021. Accessed May 31, 2021. To view the most recent version, visit NCCN.org

  • 3.

    Ko H, Baghdadi Y, Love C, et al. Clinical utility of 18F-FDG PET/CT in staging localized breast cancer before initiating preoperative systemic therapy. J Natl Compr Canc Netw 2020;18:12401246.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Srour MK, Amersi F. Response to letter to the editor: 18FDG-PET/CT imaging in breast cancer patients with clinical stage IIB or higher. Ann Surg Oncol 2020;27:17101711.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Groheux D, Hindié E, Delord M, et al. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst 2012;104:18791887.

  • 6.

    Ulaner GA. PET/CT for patients with breast cancer: where is the clinical impact? AJR Am J Roentgenol 2019;213:254265.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 104 104 48
PDF Downloads 94 94 48
EPUB Downloads 0 0 0